Our findings indicate that Ephexin1, which is markedly increased in cancer stem cells from CRC patients, is influenced by K-Ras mutations [22, 24] and impacts the Wnt/β-catenin pathway, potentially leading to unregulated stem cell proliferation. The gene discussed is KRAS; the disease is cancer.